Email from area hospital about Evusheld.
————————
There has been much news the last week about a monoclonal antibody drug therapy that works to keep people who have weakened immune systems from getting infected with COVID-19. Here's some background about this therapy, who it’s for, and when people will be able to receive it.
The drug is AstraZeneca’s Evusheld™ (tixagevimab and cilgavimab). It is an investigational medicine that has emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA).
Evusheld is a monoclonal antibody designed to provide additional immunity and prevent COVID-19 in individuals 12 years of age or older who are moderately to severely immunocompromised. These individuals may not be able to generate a strong enough immune response from the COVID-19 vaccine, making them vulnerable to severe illness. Evusheld may also be used in individuals who are not able to receive the available COVID-19 vaccines due to a history of severe adverse reaction.
Please know there is an extremely limited supply of Evusheld, which prevents us from being able to offer this medication to everyone who may be eligible at this time. As a result of this limited supply, Dartmouth-Hitchcock Health (D-HH) will be identifying those patients who are most vulnerable to severe illness based on their risk of complications from COVID-19. We will offer Evusheld to the most vulnerable patients first, and we will continue to provide it in the weeks and months ahead. Read more on our Preventive Measures for Immunocompromised Patients web page.
https://www.dartmouth-hitchcock.org/...ntive-measures